1 Introduction (Page No. – 14)
1.1 Objectives of the Study
1.2 Cancer Immunotherapy Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
2 Research Methodology (Page No. – 18)
2.1 Cancer Immunotherapy Market Size Estimation
2.2 Cancer Immunotherapy Market Breakdown and Data Triangulation
2.3 Cancer Immunotherapy Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 25)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
4 Premium Insights (Page No. – 30)
4.1 Lucrative Opportunities in the Cancer Immunotherapy Market
5 Market Overview (Page No. – 34)
5.1 Introduction
5.1.1 Drivers
5.1.1.1 Rise in Incidence Rate of Cancer Worldwide
5.1.1.2 Increase in Adoption of Immunotherapy Over Other Treatment Options
5.1.1.3 Development of Bioinformatics Tools are Enhancing Drug Development Process
5.1.2 Restraints
5.1.2.1 High Cost of Treatment
5.1.3 Opportunities
5.1.3.1 Increase in Clinical Trials Against Several Types of Cancers in Immunotherapy
5.1.3.2 High Growth Projections in the Developing Countries
5.1.4 Challenges
5.1.4.1 Availability of Limited Funds to Initiate Clinical Trials
5.1.4.2 Complexity of Cancer May Limit the Immune Response
5.2 Overview of Global Cancer Immunotherapy Funding
6 Industry Trends (Page No. – 42)
6.1 Global Trends in Cancer Immunotherapy Market
6.1.1 Opdivo (Niolumab) and Keytruda (Pembrolizumab) Fda Approval in U.S. Increases Hope Amongst Lung Cancer Patients
6.1.2 Combination Immunotherapy Potential Way to Treat Melanoma
6.1.3 U.S. Cancer Immunotherapy Research Community Builds Hope to Combat Cancer By 2020
6.1.4 U.K. Scientists Project A Change in the Means of Treatment for Cancer With Quality Therapies
6.1.5 World is Moving Toward Personalized Immunotherapy
6.1.6 A Combination of Modern Immunotherapy and Traditional Chinese Medicines Continues to Increase Survival Rate of Patients in China
6.2 Pricing Variations in Global Cancer Immunotherapy Market
6.3 Small Players Getting Together to Make Long Term Impact in Cancer Immunotherapy Market
6.4 Attractions for Pharmaceutical Industry
6.5 Heat Map for Variations in Cancer Immunotherapy for Different Types of Cancers
6.5.1 Breast Cancer
6.5.2 Lung Cancer
6.5.3 Multiple Myeloma
6.5.4 Lymphoma
7 Cancer Immunotherapy Market, By Product Type (Page No. – 53)
7.1 Introduction
7.2 Monoclonal Antibodies
7.2.1 Naked Monoclonal Antibodies
7.2.2 Conjugated Monoclonal Antibodies
7.2.3 Bispecific Monoclonal Antibodies
7.3 Vaccines
7.3.1 Prophylactic Vaccines
7.3.2 Therapeutic Vaccines
7.4 Check Point Inhibitors
7.4.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
7.4.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
7.5.2 Dendritic Cells
7.6 Immunomodulators
7.6.1 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF)
7.6.2 Interferons (IFN)
7.6.3 Interleukins (IL)
7.6.4 Oncolytic Virus
7.6.4.1 Immunotherapy
7.6.4.1 Immunity as an Obstacle
7.6.4.2 Immunity as an Ally
7.6.4.3 Approved Products & Clinical Trails
8 Cancer Immunotherapy Market, By Application (Page No. – 72)
8.1 Introduction
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Multiple Myeloma
8.5 Colorectal Cancer
8.6 Head & Neck Cancer
8.7 Prostate Cancer
8.8 Melanoma
8.9 Other Cancer Types
9 Cancer Immunotherapy Market, By End User (Page No. – 84)
9.1 Introduction
9.2 Hospital
9.3 Clinics and Others
10 Cancer Immunotherapy Market, By Region (Page No. – 88)
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Rest of the World (RoW)
11 Competitive Landscape (Page No. – 100)
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Approvals
11.3.2 Agreements, Partnerships, and Collaborations
11.3.3 Acquisitions
11.3.4 Expansions
11.3.5 Other Developments
12 Company Profile (Page No. – 109)
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
12.1 Amgen Inc.
12.2 Astrazeneca
12.3 Bayer AG
12.4 Bristol-Myers Squibb
12.5 Eli Lilly and Company
12.6 Janssen Global Services, LLC (Johnson and Johnson)
12.7 Merck
12.8 Novartis
12.9 Pfizer
12.10 F. Hoffmann-LA Roche Ltd
*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 137)
13.1 Insights From Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT : Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
Table 1 Overview of Funding Pattern in Different Types of Cancer By Nih, U.S., 2012–2017 (USD Million)
Table 2 Overview of Key Funding in Cancer Immunotherapy Market, 2016
Table 3 Conventional Cancer Therapy Versus Cancer Immunotherapy
Table 4 Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 5 Cancer Monoclonal Antibodies Market Size, By Subtype, 2014–2021 (USD Million)
Table 6 Cancer Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 7 Naked Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 8 Conjugated Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 9 Bispecific Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Million)
Table 10 Vaccines Market, By Subtype, 2014–2021 (USD Million)
Table 11 Vaccines Market, By Region, 2014–2021 (USD Million)
Table 12 Prophylactic Vaccines Market Size, 2014–2021 (USD Million)
Table 13 Therapeutic Vaccines Market, By Region, 2014–2021 (USD Million)
Table 14 Checkpoint Inhibitors Market Size, By Subtype, 2014–2021 (USD Million)
Table 15 Checkpoint Inhibitors Market, By Region, 2014–2021 (USD Million)
Table 16 Cytoxic T-Lymphocyte Market Size, By Region, 2014–2021 (USD Million)
Table 17 Cytoxic T-Lymphocyte Market Size, By Region, 2014–2021 (USD Million)
Table 18 Immunomodulators Market Size, By Subtype, 2014–2021 (USD Million)
Table 19 Immunomodulators Market Size, By Region, 2014–2021 (USD Million)
Table 20 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Market Size, By Region, 2014–2021 (USD Million)
Table 21 Interferons Market Size, By Region, 2014–2021 (USD Million)
Table 22 Interleukins Market Size, By Region, 2014–2021 (USD Million)
Table 23 Cancer Immunotherapy Market Size, By Application, 2014–2021 (USD Million)
Table 24 Lung Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 25 Breast Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 26 Multiple Myeloma Market Size, By Region, 2014–2021 (USD Million)
Table 27 Colorectal Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 28 Head & Neck Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 29 Prostate Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 30 Melanoma Market Size, By Region, 2014–2021 (USD Million)
Table 31 Other Types of Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 32 Cancer Immunotherapy Market Size, By End User, 2014–2021 (USD Million)
Table 33 Hospitals Market Size, By Region, 2014–2021 (USD Million)
Table 34 Clinics and Others Market Size, By Region, 2014–2021 (USD Million)
Table 35 Cancer Immunotherapy Market Size, By Region, 2014–2021 (USD Million)
Table 36 North America: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 37 Europe: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 38 Asia-Pacific: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 39 RoW: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 40 Approvals, 2013–2016
Table 41 Agreements, Partnerships, and Collaborations, 2013–2016
Table 42 Acquisitions, 2013–2016
Table 43 Expansions, 2013–2016
List of Figures (69 Figures)
Figure 1 Classification of Cancer Immunotherapy
Figure 2 Research Design
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 The Monoclonal Antibody Segment is Expected to Lead the Global Cancer Immunotherapy Market During the Forecast Period
Figure 8 The Lung Cancer Segment to Lead the Global Cancer Immunotherapy Market in 2016
Figure 9 Hospitals are Major End Users of the Global Cancer Immunotherapy Market
Figure 10 North America Led the Global Cancer Immunotherapy Market in 2015
Figure 11 Future of Cancer Immunotherapeutics
Figure 12 Global Cancer Immunotherapy Market to Witness High Growth During the Forecast Period
Figure 13 Lung Cancer Application Dominated the Global Cancer Immunotherapy Market, 2016
Figure 14 Asia-Pacific to Witness the Fastest Growth During the Forecast Period
Figure 15 Lung Cancer to Witness the Fastest Growth During the Forecast Period in the Cancer Immunotherapy Market
Figure 16 Drivers, Restraints, Opportunities, and Challenges
Figure 17 Population Forecasts for All Cancers Excluding Non-Melanoma Skin Cancer, 2012 vs 2020
Figure 18 Pricing Trend of Imbruvica Across Major Pharmaceutical Market in 2016
Figure 19 Heat Map Showing Variations in Immunotherapy Drugs Used for Breast Cancer
Figure 20 Annual Cost of Breast Cancer Immunotherapy, 2016
Figure 21 Heat Map Showing Variations in Immunotherapy Drugs Used for Lung Cancer
Figure 22 Annual Cost of Lung Cancer Immunotherapy, 2016
Figure 23 Heat Map Showing Variations in Immunotherapy Drugs Used for Multiple Myeloma
Figure 24 Annual Cost of Multiple Myeloma Immunotherapy, 2016
Figure 25 Heat Map Showing Variations in Immunotherapy Drugs Used for Lymphoma
Figure 26 Annual Cost of Lymphoma Immunotherapy, 2016
Figure 27 Cancer Immunotherapy Market Size, By Product Type
Figure 28 Monoclonal Antibodies Segment to Dominate the Cancer Immunotherapy Market Size in 2016
Figure 29 Naked Monoclonal Antibodies to Account for the Largest Share in 2016
Figure 30 North America to Account for the Largest Share of the Cancer Monoclonal Antibodies Market in 2016
Figure 31 Vaccines Market Size, By Subtype, 2016–2021 (USD Million)
Figure 32 Asia-Pacific Expected to Be the Fastest-Growing Regional Segment of the Vaccines Market
Figure 33 Programmed Death 1(PD-1) is Expected to Be the Fastest-Growing Segment of the Check Point Inhibitors Market
Figure 34 RoW is Expected to Account the Fastest-Growing Regional Segment of the Checkpoint Inhibitors Market
Figure 35 GM-CSF & G-CSF Segment is Expected to Dominate the Immunomodulators Market in 2016
Figure 36 North America is Expected to Account for the Largest Share in the Immunomodulators Market Through 2021
Figure 37 Cancer Immunotherapy Market, By Application
Figure 38 Lung Cancer Segment Leads the Cancer Immunotherapy Market Size in 2016
Figure 39 North America Accounts for the Largest Share of the Lung Cancer Immunotherapy Market in 2016
Figure 40 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Breast Cancer in 2016
Figure 41 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Multiple Myeloma in 2016
Figure 42 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Colorectal Cancer in 2016
Figure 43 North America Estimated to Account for the Largest Share of the Immunotherapy Market for Head & Neck Cancer in 2016
Figure 44 North America Estimated to Dominate the Immunotherapy Market for Prostate Cancer in 2016
Figure 45 North America is Projected to Be the Fastest-Growing Region in the Cancer Immunotherapy Market for Melanoma During the Forecast Period
Figure 46 Asia-Pacific is Projected to Be the Fastest-Growing Region in the Immunotherapy Market for Other Cancer Types, 2016-2021
Figure 47 Cancer Immunotherapy Market, By End User, 2016 vs 2021 (USD Million)
Figure 48 Hospitals Market Size, 2016 vs 2021, By Region (USD Million)
Figure 49 Clinics and Others Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 50 Geographic Snapshot: Asia-Pacific is Projected to Be the Fastest-Growing Region During the Forecast Period
Figure 51 Checkpoint Inhibitors Segment is Projected to Grow at the Highest Rate From 2016 to 2021
Figure 52 North America: Cancer Immunotherapy Market Snapshot, 2016
Figure 53 The Check Point Inhibitors is Projected to Be the Fastest-Growing Market in North America During the Forecast Period
Figure 54 Monoclonal Antibodies Segment is Projected to Dominate the Cancer Immunotherapy Market in Europe Till 2021
Figure 55 Asia-Pacific: Cancer Immunotherapy Market Snapshot, 2016
Figure 56 Checkpoint Inhibitors Segment is Expected to Lead the Cancer Immunotherapy Market in the RoW Region Till 2021
Figure 57 Companies Adopted Approvals as Their Key Growth Strategy Over the Last Three Years
Figure 58 Global Cancer Immunotherapy Market Share, By Key Player, 2015
Figure 59 Approvals: the Key Growth Strategy Adopted By Market Players From 2013 to 2015
Figure 60 Amgen: Company Snapshot
Figure 61 Astrazeneca: Company Snapshot
Figure 62 Bayer AG: Company Snapshot
Figure 63 Bristol-Myers Squibb: Company Snapshot
Figure 64 Eli Lilly and Company: Company Snapshot
Figure 65 Janssen Global Services, LLC: Company Snapshot
Figure 66 Merck: Company Snapshot
Figure 67 Novartis; Company Snapshot
Figure 68 Pfizer : Company Snapshot
Figure 69 F. Hoffmann-LA Roche Ltd.: Company Snapshot
【レポートのキーワード】
がん免疫療法、癌治療薬、細胞治療、モノクローナル抗体、がんワクチン、免疫チェックポイント阻害療、免疫調節薬
【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。
